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Rh discrepancies caused by variable reactivity of partial and
weak D types with different serologic techniques
Gregory A. Denomme, Louann R. Dake, Daniel Vilensky, Lily Ramyar, and W. John Judd
BACKGROUND: RhD discrepancies between current
and historical results are problematic to resolve. The
investigation of 10 discrepancies is reported here.
STUDY DESIGN: Samples identified were those that
reacted by automated gel technology and were nega-
tive with an FDA-approved reagent. Reactivity with a
commercially available panel of monoclonal anti-D was
performed. Genomic DNA was evaluated for RHD
alleles with multiplex RHD exon polymerase chain reac-
tion (PCR), weak D PCR-restriction fragment length
polymorphism, and RHD exon 5 and 7 sequence
analyses.
RESULTS: The monoclonal anti-D panel identified two
samples as DVa, yet possessed the DAR allele. Two
weak D Type 1 samples had a similar monoclonal
anti-D profile, but only one reacted directly with one of
two FDA-approved anti-D. Only two of four weak D
Type 2 samples reacted directly with one FDA-approved
anti-D, and their D epitope profile differed.
CONCLUSIONS: The monoclonal anti-D reagents did
not distinguish between partial and weak D Types 1 and
2. Weak D Types 1 and 2 do not show consistent reac-
tivity with FDA-approved reagents and technology. To
limit anti-D alloimmunization, it is recommended that
samples yielding an immediate-spin tube test cutoff
score of not more than 5 (i.e., 1+ agglutination) or a
score of not more than 8 (i.e., 2+ hemagglutination)
by gel technology be considered D– for transfusion and
Rh immune globulin prophylaxis. That tube test anti-D
reagents react poorly with some Weak D Types 1 and 2
red cells is problematic, inasmuch as they should be
considered D+ for transfusion and prenatal care.
Molecular tests that distinguish common partial and
Weak D types provide the solution to resolving D
antigen discrepancies.
R
hD variants are classified for clinical purposes
into one of three groups: partial D variants
(including category), weak D types, or nonfunc-
tional and D-elution alleles.1 Partial D variants
lack D antigen epitopes,2 and weak D types generally
present all D epitopes albeit some epitopes show variabil-
ity depending on the monoclonal anti-D.3,4 Individuals
who harbor partial D variant alleles have the potential to
make alloanti-D,5 whereas common weak D types do not
pose such a risk.6 The distinction is important because the
appropriate assignment of D antigen status determines
the selection of blood products and perinatal manage-
ment to prevent anti-D hemolytic disease of the fetus and
newborn.
The intent of FDA-approved anti-D serologic typing
reagents is to ensure that the appropriate D antigen status
is assigned, such that the most common partial D variants
(e.g., DVI) are nonreactive by the immediate-spin (IS) tube
test and therefore are classified as D–. Exceptions do exist,
however, and in light of changing technologies and
reagents along with the multitude of variants with weak-
ened or altered expression, discrepancies are noted.7,8
When D antigen discrepancies arise clinicians are faced
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with assigning the appropriate D antigen status, so that
the appropriate (D– or D+) blood products can be admin-
istered. Moreover, in an era of informed consent, the
impact of a D antigen discrepancy can create confusion
over the use of Rh immune globulin.9
The D antigen is a 417 amino acid moiety with a ter-
tiary conformation that can be described in a 30 epitope
model.10,11 More than 175 alleles have been characterized
at molecular level.12 Some D variants have similar epitope
profiles when evaluated with monoclonal anti-D reagents.
For example, DBS, DFR, and some category DVa variants
share some exon 5 amino acid replacements and some D
epitopes.13 For the most part, similar serologic profiles do
not create a problem for the interpretation of D antigen
status when a partial D variant is suspected. The DAR
allele is one such allele that is at risk for anti-D alloimmu-
nization due to the lack of D antigen epitopes. With the
37-epitope model, DAR is thought to lack epitopes 2, 4, 7,
10, 11, 17, 18, 21, 22, 23, and 31 to 35 and to have an altered
expression for many of the remaining epitopes.14 Thus,
specific monoclonal anti-D reagents have become
popular reagents to identify partial D variants quickly,
which help clinicians make an informed decision on the
appropriate D antigen status. Alternatively, molecular
analyses including direct nucleotide sequencing have
been used to resolve RHD discrepancies, although these
specialized techniques have a less than ideal turnaround
time.15-18
We evaluated a group of 10 patients who were identi-
fied on the basis of a D antigen discrepancy with historical
records or tube test results. We evaluated the expression of
the D antigen with three FDA-approved anti-D reagents
and a panel of non–FDA-approved monoclonal anti-D
reagents and performed molecular analyses to resolve the
discrepancies. We show here that the DAR allele and cat-
egory DVa variants have similar monoclonal anti-D pro-
files. More importantly, we show that an FDA-approved
reagent can have variable reactivity with various examples
of weak D types, and in some instances, these weak D




Samples were initially identified on the basis of a discrep-
ancy between a newly implemented automated gel tech-
nology test (ProVue, Ortho Clinical Diagnostics, Raritan,
NJ) and historical records. In all instances, the gel Rh
typing test indicated that the patient was D+ when the
patient’s historical record was D–. Other discrepancies
were noted when an IS tube test was performed to confirm
the Rh type before the release of electronic crossmatch-
compatible blood.
Serologic analysis
Once a discrepancy was noted with the automated gel test,
the samples were further analyzed by IS tube test with two
anti-D reagents (Gamma-clone, Immucor, Inc., Norcross,
GA; BioClone, Ortho Clinical Diagnostics, Raritan, NJ) in
accordance with the manufacturers’ recommendations
for the IS tube test. Hemagglutination was graded and
scored as described by Marsh.19 In addition, the red cells
(RBCs) were tested with a panel of monoclonal antibodies
(MoAbs) indicated as A through L (Alba Bioscience,
Edinburgh, UK). Included in the serologic analysis of the
discrepancies was a complete Rh C, c, E, e phenotype, with
the most probable genotype method used to assign the Rh
genotype.20
RHD molecular analyses
Samples with a discrepant IS tube test result were ana-
lyzed for partial D variants with a multiplex polymerase
chain reaction (PCR) protocol for seven RHD-specific
exons 3 through 7 and 9 and exon 10.21,22 Those samples
with RHD-specific exons were further analyzed for the
presence of weak D Type 1 through Type 3 by PCR-
restriction fragment length polymorphism (RFLP).3,23,24
Samples that could not be assigned an RHD allele were
subjected to direct automated sequencing of RHD
exon 5.23 A separate PCR amplification product with the
exon 7 primers alone was subjected to direct sequence
analysis to evaluate the 1025-nucleotide position for pres-
ence of the DAR allele. Comparative analysis with the ref-
erence RHD sequence NM_016124 was performed with
the pair-wise basic local alignment search tool (BLAST).25
RESULTS
Monoclonal anti-D pattern
The MoAbs were chosen on the basis of the potential to
provide information for the presence of partial D pheno-
types. Table 1 summarizes the reactivity pattern of these
monoclonal anti-D reagents evaluated with archived
frozen RBCs of various known partial D types including
partial DIIIa, DIIIb, and DIIIc; DIVa; and DIVb. Consistent
with the manufacturer’s monograph, the monoclonal
anti-D reagents E and I are nonreactive with partial DVa
RBCs. The precise allelic classification of our archived DVa
RBCs cannot be determined, however. Monoclonal B was
reactive with a single example of partial DIVa but not
DIVb. In addition, some of our archived cells reacted with
certain monoclonal anti-D in difference to the manufac-
turer’s reaction profile. The following monoclonal anti-D
were reactive with our cells: monoclonal A with DBT; C
with DVa and DFR; D with DBT; H with DII; and L with
RoHAR. The serologic reactivity with the 12 monoclonal
anti-D reagents resulted in four patterns among the 10
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discrepancy samples analyzed (Table 2). RBCs from 2
samples did not react with monoclonal anti-D reagents E
and I, suggesting a partial DVa phenotype. RBCs from 4
samples weakly reacted with monoclonal anti-D reagent I
alone. The RBCs of 4 samples did not react with mono-
clonal reagent I; 1 reacted weakly with reagent J.
Reactivity of DAR and weak D types
Multiplex RHD-specific PCR indicated that the two sero-
logically DVa samples had nucleotide changes in exon 5
due to a lack of amplification of this exon. Direct nucle-
otide sequence analyses of exons 5 and 7 revealed a DAR
(weak D Type 4.2) allele. Two samples were weak D Type 1
and reacted with monoclonal anti-D reagent I; a genotype
could not be assigned for these samples. Three other
samples did not react with monoclonal anti-D reagent I
alone and consisted of one R1r sample for which exon 5
could not be amplified and two R2r samples that were
weak D Type 2. An additional two R2r samples demon-
strating weak reactivity with monoclonal anti-D reagent I
alone were weak D Type 2. Therefore, serologic patterns
were inconsistent among the four weak D Type 2 samples
analyzed.
Discrepancies by commercial anti-D for partial D
and weak D types
The IS tube tests with one FDA-approved reagent were not
in agreement for the two DAR samples; one of two was
positive with the BioClone reagent. Similarly, one of two
weak D Type 1 samples was positive with the BioClone
reagent (score, 5). Divergent reactivity was noted also for
the four weak D Type 2 samples and the lack of reactivity
did not correlate with monoclonal anti-D reagent I. A
comparison between the monoclonal anti-D and FDA-
TABLE 1. Monoclonal anti-D epitope profiles for partial D phenotypes (summarized from in-house testing) and
the reactivity with FDA-approved antiserum samples*
Monoclonal anti-D epitope profile IS anti-D result
A B C D E F G H I J K L P G B
DII + + + + + NT + + + + + + + + +
DIIIa + + + + + + + + + + + + + + +
DIIIb 0 + + + NT + + + + + + + + + +
DIIIc + + + + NT + + + + + + + NT NT NT
DIVa + + 0 + 0 0 0 0 0 + + + + + +
DIVb + 0 0 + 0 0 0 0 0 + + + NT NT NT
DVa + + + + 0 + + + 0 + + + + + 0
DVI 0 + 0 0 0 + + + 0 0 0 0 0 0 0
DVII + + + + + + + + + 0 + + NT NT NT
DFR (+) + + + + NT + + 0 0 + 0 0 0 0
DBT + 0 0 + 0 NT 0 0 0 + 0 + + + 0
RoHAR 0 0 0 0 0 0 0 0 0 0 0 + +  0
* A to L = monoclonal anti-D from Alba BioSciences. P = ProVue gel test; G = Gamma-clone tube test; B = BioClone tube test. + = positive;
0 = negative; (+) = weak;  = very weak; NT = not tested.
TABLE 2. Results of the monoclonal anti-D epitope profile, FDA-approved anti-D serotyping, and the molecular




Monoclonal anti-D epitope reactivity Anti-D score
A B C D E F G H I J K L P G B
Patients
Ror DAR DVa 10 10 10 10 0 10 10 10 0 10 10 10 8 8 5
Ror DAR DVa 10 10 9 10 0 10 10 10 0 10 10 10 8 8 0
R1r Weak D Type 1 10 10 10 10 10 10 10 10 5 10 10 10 8 10 5
R1r Weak D Type 1 10 10 10 10 10 10 10 10 5 10 10 10 8 7 0
R1r Unknown 10 10 10 10 9 10 10 10 0 6 10 10 8 10 5
R1r Unknown 10 10 10 10 10 10 10 10 0 10 10 10 8 10 6
R2r Weak D Type 2 10 10 10 10 10 10 10 10 0 9 10 10 8 10 5
R2r Weak D Type 2 10 10 10 10 10 10 10 10 5 10 10 10 8 8 5
R2r Weak D Type 2 10 10 10 10 10 10 10 10 0 10 10 10 8 7 0
R2r Weak D Type 2 10 10 10 10 10 10 10 10 6 10 10 10 8 7 0
Controls
R1r RHD+ Normal 12 12 12 12 11 12 11 11 11 12 12 12 11 11 12
R2r RHD+ Normal 11 11 11 11 11 11 11 11 11 11 11 11 12 12 12
rr RHD– Negative 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
* DVa = shares epitope similarity with partial DVa phenotype. P = ProVue gel test; G = Gamma-clone tube test; B = BioClone tube test.
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approved reagents are summarized in Table 2. Most
importantly, a direct comparison of the results of the three
FDA-approved anti-D reagents alone for the samples with
the pattern for known partial Ds (Table 1, IS anti-D result)
suggests that one DAR, one weak D Type 1, and two
weak D Type 2 would be classified as partial DV or DAR
types. Therefore, consistent with the manufacturer’s reac-
tion profile, it was not possible to categorize the discrep-
ancies as partial or weak D Types 1 or 2 on the basis of
serology alone.
DISCUSSION
FDA-approved reagents and technologies are used in the
clinical laboratory to ensure the accurate assignment of
the D antigen for potential transfusion recipients and
pregnant women. The choice of blood products and peri-
natal care rely heavily on the appropriate serologic D
antigen status; patients who express partial D variants
should be considered D–. In light of changing reagents
and technologies, D antigen discrepancies between exist-
ing tests and historical records occur. The implementation
of a useful clinical paradigm to resolve these discrepancies
is important for appropriate transfusion and perinatal
management.
We found D antigen discrepancies between a recently
implemented gel technology in our institution and his-
torical records or the result of tube test anti-D performed
as part of the electronic crossmatch process. We used a
large series of monoclonal anti-D reagents to evaluate
the epitope profiles of these samples as a way to resolve
discrepancies. In addition, we performed a multiplex
sequence-specific priming PCR, PCR-RFLP, and
sequenced exon 5 to identify common partial and weak D
types.
Our studies found that the DAR phenotype and the
partial D category DVa have similar monoclonal anti-D
epitope profiles. This observation is not surprising given
the common nucleotide changes in exon 5 shared by these
two partial D variants. The nucleotide change at position
1025 of exon 7 confirmed the presence of the DAR allele,
and the assignment did not have an impact on the choice
of blood products or perinatal care. Serologic reactivity
with BioClone anti-D, however, showed a disparity for the
two DAR samples. One sample reacted (score 5) and the
other did not react with the IS test method. The most
probable genotype of both samples was Ror and because
the assignment is based on probability, the disparity pos-
sibly could be explained on the basis of one sample rep-
resenting the RoRo phenotype, that is, homozygous for
RHD. For the monoclonal anti-D profile and molecular
analyses to be consistent with the presence of two RHD
alleles, however, both would have to represent the DAR
allele as suggested in the product monograph. We have
had one other Ror sample expressing DAR that did not
react with the BioClone reagent, which was not tested with
the monoclonal anti-D reagents (data not shown). Regard-
less, weak or negative reactivity with one FDA-approved
anti-D caused us to perform the monoclonal anti-D
profile, which indicated a partial D phenotype and helped
to assign an D– status.
Two examples of Weak D type 1 and several examples
of Weak D type 2 showed disparity with an FDA-approved
anti-D. Both weak D Types 1 and 2 show heterogeneity in
their reactivity with the BioClone reagent. The two weak D
Type 1 samples differed in their IS tube test reactivity with
the BioClone reagent, and a similar observation was seen
with the weak D Type 2; two of four did not react with the
BioClone reagent. Moreover, the lack of reactivity with the
BioClone reagent was inconsistent with a monoclonal
anti-D that was nonreactive with two of four weak D
Type 2 (Table 2).
An exhaustive evaluation of D antigen density and
epitope distribution among partial D has been performed
in the past.2,26-29 The variability of expression for similar
examples of weak D Types 1 and 2 is lacking, however.
Moreover, reduced reactivity with monoclonal anti-D
reagents can be viewed as indicative of a partial D allele.
Therefore, if results of the monoclonal anti-D profile were
applied to some examples of weak D Types 1 and 2, then
they would be deemed D– and the patients would receive
D– blood or be given Rh immune globulin.
The most likely reason for the variable expression
among similar weak D types is unknown. Aside from the
variable expression known to exist for partial D, previous
studies showed that the expression of the D antigen var-
ies.30,31 Other than the cis-trans effect exerted in the pres-
ence of RHCe,32 no molecular mechanism for this
variation has been identified. Possibly, there are noncod-
ing differences among similar variants that may affect
the half life of the mRNA, or alternatively, there may be
subtle differences in some other moiety of the Rh
complex, which affects the expression of the D antigen as
has been previously hypothesized.30 In our opinion, tube
tests have the highest degree of subjectivity and result in
the most variability. The definition of “immediate spin” is
difficult to define when one considers that samples can
be tested alone or as part of a batch. Moreover, small dif-
ferences in the testing temperature, protein concen-
tration, and other technical factors such as minor
centrifugation speed differences or how the RBC pellet is
dislodged can affect the degree of agglutination and
likely contribute to the variable results for manual tube
tests even for repeat tests performed on the same
sample.
The variation in expression and ultimately the D
antigen status of patients who harbor alleles of weak D
alleles still pose a challenge for the transfusion service. In
our hands, a change in method (introduction of gel tech-
nology) resulted in Rh discrepancies. The data presented
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here of our investigations show that a serologic solution to
the positive identification of weak and partial D variants is
unlikely. Therefore, we recommend that samples yielding
an IS tube test cutoff score of not more than 5 (i.e., 1+
hemagglutination) or a score of not more than 8 (i.e., 2+
hemagglutination) by gel technology, be considered D–
for the purpose of transfusion and Rh immune globulin
prophylaxis.
Unfortunately, serology alone does not resolve the
issue of those weak D types not at risk of making anti-D.
Molecular tests that can distinguish common partial and
weak D types provide the best solution to the resolution of
an accurate D antigen status. In our small study, the D
antigen status of 8 of 10 patients was resolved with
three molecular tests. Future work should focus on
improvements to the turnaround time for resolving Rh
discrepancies.
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